Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Air Microbiology | 23 | 2021 | 95 | 6.030 |
Why?
|
Disinfection | 18 | 2021 | 207 | 5.060 |
Why?
|
Tuberculosis, Pulmonary | 30 | 2024 | 830 | 4.650 |
Why?
|
Tuberculosis | 45 | 2022 | 2017 | 4.380 |
Why?
|
Tuberculosis, Multidrug-Resistant | 23 | 2021 | 934 | 3.600 |
Why?
|
Antitubercular Agents | 28 | 2024 | 1374 | 3.540 |
Why?
|
Ultraviolet Rays | 21 | 2023 | 1078 | 3.500 |
Why?
|
Mycobacterium tuberculosis | 30 | 2021 | 1912 | 3.140 |
Why?
|
Infection Control | 19 | 2020 | 983 | 2.920 |
Why?
|
Ventilation | 13 | 2015 | 128 | 2.100 |
Why?
|
Cross Infection | 23 | 2017 | 1422 | 1.990 |
Why?
|
Latent Tuberculosis | 7 | 2022 | 224 | 1.350 |
Why?
|
Communicable Disease Control | 8 | 2017 | 846 | 1.340 |
Why?
|
Tuberculin Test | 9 | 2022 | 205 | 1.290 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 4 | 2014 | 85 | 0.900 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 6 | 2020 | 250 | 0.810 |
Why?
|
Cough | 3 | 2024 | 594 | 0.810 |
Why?
|
Measles | 2 | 2020 | 181 | 0.720 |
Why?
|
Disease Transmission, Infectious | 5 | 2020 | 561 | 0.710 |
Why?
|
Air Pollution, Indoor | 6 | 2015 | 900 | 0.700 |
Why?
|
Occupational Diseases | 8 | 2017 | 1490 | 0.700 |
Why?
|
Air Conditioning | 1 | 2020 | 54 | 0.690 |
Why?
|
Directly Observed Therapy | 3 | 2011 | 139 | 0.650 |
Why?
|
Knowledge | 1 | 2020 | 178 | 0.620 |
Why?
|
Sputum | 5 | 2024 | 505 | 0.620 |
Why?
|
Guinea Pigs | 7 | 2018 | 1308 | 0.610 |
Why?
|
Environment, Controlled | 4 | 2013 | 42 | 0.610 |
Why?
|
Health Personnel | 9 | 2019 | 3337 | 0.610 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2018 | 585 | 0.500 |
Why?
|
Diffusion of Innovation | 1 | 2020 | 730 | 0.490 |
Why?
|
Capreomycin | 1 | 2013 | 14 | 0.440 |
Why?
|
Climate Change | 1 | 2020 | 498 | 0.430 |
Why?
|
Bacteriological Techniques | 2 | 2011 | 275 | 0.430 |
Why?
|
Air Movements | 1 | 2013 | 40 | 0.430 |
Why?
|
Powders | 1 | 2013 | 80 | 0.430 |
Why?
|
Respiratory Protective Devices | 4 | 2015 | 47 | 0.420 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2018 | 662 | 0.410 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3093 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3215 | 0.400 |
Why?
|
Altruism | 1 | 2014 | 208 | 0.400 |
Why?
|
Occupational Exposure | 4 | 2017 | 1814 | 0.390 |
Why?
|
Pandemics | 4 | 2023 | 8663 | 0.370 |
Why?
|
Aerosols | 4 | 2020 | 635 | 0.370 |
Why?
|
Reagent Kits, Diagnostic | 2 | 2009 | 239 | 0.350 |
Why?
|
Contact Tracing | 3 | 2011 | 272 | 0.340 |
Why?
|
Research | 1 | 2018 | 1976 | 0.340 |
Why?
|
Anti-Infective Agents | 2 | 2021 | 983 | 0.340 |
Why?
|
Travel | 2 | 2014 | 796 | 0.330 |
Why?
|
Masks | 1 | 2012 | 209 | 0.330 |
Why?
|
Radiometry | 2 | 2012 | 812 | 0.310 |
Why?
|
Models, Organizational | 1 | 2011 | 544 | 0.300 |
Why?
|
National Health Programs | 1 | 2011 | 440 | 0.300 |
Why?
|
Humans | 103 | 2024 | 761222 | 0.290 |
Why?
|
Keratoconjunctivitis | 1 | 2008 | 40 | 0.290 |
Why?
|
Photosensitivity Disorders | 1 | 2008 | 79 | 0.290 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 1111 | 0.290 |
Why?
|
Family Characteristics | 1 | 2011 | 992 | 0.270 |
Why?
|
Early Diagnosis | 6 | 2019 | 1186 | 0.260 |
Why?
|
Isoniazid | 6 | 2015 | 283 | 0.260 |
Why?
|
Drug Monitoring | 1 | 2011 | 961 | 0.250 |
Why?
|
Rifampin | 4 | 2017 | 338 | 0.250 |
Why?
|
Influenza A virus | 1 | 2008 | 458 | 0.240 |
Why?
|
Peru | 5 | 2024 | 888 | 0.240 |
Why?
|
Pericarditis, Tuberculous | 1 | 2004 | 8 | 0.240 |
Why?
|
Diagnostic Tests, Routine | 1 | 2010 | 788 | 0.240 |
Why?
|
Health Resources | 1 | 2010 | 934 | 0.230 |
Why?
|
Microbial Sensitivity Tests | 4 | 2021 | 1936 | 0.230 |
Why?
|
Influenza, Human | 2 | 2020 | 1521 | 0.220 |
Why?
|
Health Services Accessibility | 3 | 2011 | 5426 | 0.220 |
Why?
|
Health Services Needs and Demand | 1 | 2011 | 1401 | 0.220 |
Why?
|
Disease Outbreaks | 5 | 2007 | 1747 | 0.220 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 940 | 0.220 |
Why?
|
Breath Tests | 1 | 2024 | 299 | 0.210 |
Why?
|
Coronavirus 229E, Human | 1 | 2023 | 16 | 0.210 |
Why?
|
Aerospace Medicine | 1 | 2004 | 95 | 0.210 |
Why?
|
Molecular Epidemiology | 2 | 2002 | 470 | 0.210 |
Why?
|
Developing Countries | 5 | 2010 | 2863 | 0.210 |
Why?
|
Pericardial Effusion | 1 | 2004 | 247 | 0.200 |
Why?
|
Administration, Inhalation | 3 | 2015 | 1159 | 0.200 |
Why?
|
BCG Vaccine | 2 | 2014 | 369 | 0.190 |
Why?
|
Environmental Exposure | 3 | 2008 | 4479 | 0.190 |
Why?
|
Virus Inactivation | 1 | 2021 | 19 | 0.190 |
Why?
|
Emigration and Immigration | 2 | 2002 | 397 | 0.190 |
Why?
|
Patient Isolation | 2 | 1998 | 100 | 0.180 |
Why?
|
Bioterrorism | 3 | 2005 | 144 | 0.160 |
Why?
|
Clone Cells | 1 | 2002 | 1668 | 0.160 |
Why?
|
South Africa | 4 | 2022 | 1843 | 0.160 |
Why?
|
Sensitivity and Specificity | 6 | 2024 | 14675 | 0.150 |
Why?
|
Humidity | 2 | 2013 | 205 | 0.150 |
Why?
|
HIV Infections | 7 | 2015 | 17348 | 0.150 |
Why?
|
Treatment Outcome | 13 | 2019 | 64681 | 0.150 |
Why?
|
Interferon-gamma | 3 | 2013 | 3155 | 0.150 |
Why?
|
Community-Acquired Infections | 2 | 2019 | 469 | 0.150 |
Why?
|
Endemic Diseases | 1 | 2018 | 191 | 0.150 |
Why?
|
Pulmonary Medicine | 1 | 2019 | 221 | 0.140 |
Why?
|
Hospitals, General | 1 | 2021 | 799 | 0.140 |
Why?
|
Hospital Units | 1 | 1997 | 142 | 0.130 |
Why?
|
Nebulizers and Vaporizers | 2 | 2015 | 139 | 0.130 |
Why?
|
Consumer Advocacy | 1 | 2017 | 83 | 0.130 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18222 | 0.130 |
Why?
|
Occupational Health | 2 | 2013 | 807 | 0.130 |
Why?
|
History, 19th Century | 1 | 2018 | 718 | 0.130 |
Why?
|
Mycobacterium | 2 | 2014 | 251 | 0.130 |
Why?
|
Dust | 1 | 2018 | 486 | 0.130 |
Why?
|
Bangladesh | 1 | 2017 | 732 | 0.120 |
Why?
|
Colistin | 1 | 2015 | 44 | 0.120 |
Why?
|
Poverty | 4 | 2010 | 2691 | 0.120 |
Why?
|
Lung Diseases | 1 | 2024 | 1910 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 610 | 0.110 |
Why?
|
Animals | 15 | 2018 | 168089 | 0.110 |
Why?
|
Environment Design | 1 | 2015 | 173 | 0.110 |
Why?
|
Dry Powder Inhalers | 1 | 2013 | 8 | 0.110 |
Why?
|
Facility Design and Construction | 2 | 2010 | 85 | 0.110 |
Why?
|
Fungi | 1 | 2016 | 337 | 0.110 |
Why?
|
Silicosis | 1 | 2013 | 47 | 0.100 |
Why?
|
Lymph Nodes | 1 | 2004 | 3461 | 0.100 |
Why?
|
Risk | 2 | 2004 | 9616 | 0.100 |
Why?
|
Attitude to Health | 1 | 2021 | 2026 | 0.100 |
Why?
|
Mining | 1 | 2013 | 93 | 0.100 |
Why?
|
Drug Resistance, Multiple | 2 | 2007 | 255 | 0.100 |
Why?
|
DNA Fingerprinting | 2 | 2002 | 114 | 0.100 |
Why?
|
Nurses | 1 | 2021 | 2477 | 0.100 |
Why?
|
Drug Therapy, Combination | 5 | 2019 | 6304 | 0.100 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 2002 | 765 | 0.100 |
Why?
|
Housing, Animal | 1 | 2011 | 47 | 0.090 |
Why?
|
Environmental Health | 1 | 1993 | 289 | 0.090 |
Why?
|
Radiation Monitoring | 1 | 2012 | 103 | 0.090 |
Why?
|
Adult | 21 | 2024 | 221120 | 0.090 |
Why?
|
Safety Management | 1 | 2016 | 761 | 0.090 |
Why?
|
Hospitalization | 4 | 2024 | 10707 | 0.090 |
Why?
|
History, 20th Century | 1 | 2018 | 2765 | 0.090 |
Why?
|
Drug Resistance, Microbial | 4 | 2002 | 826 | 0.090 |
Why?
|
Forecasting | 2 | 2015 | 2928 | 0.080 |
Why?
|
Models, Theoretical | 4 | 2013 | 3571 | 0.080 |
Why?
|
Prevalence | 5 | 2017 | 15721 | 0.080 |
Why?
|
Institutionalization | 1 | 1989 | 106 | 0.080 |
Why?
|
Nanostructures | 1 | 2014 | 551 | 0.080 |
Why?
|
Health Occupations | 1 | 1990 | 223 | 0.080 |
Why?
|
Massachusetts | 8 | 2002 | 8837 | 0.080 |
Why?
|
Sterilization | 1 | 1989 | 132 | 0.080 |
Why?
|
Male | 22 | 2024 | 360703 | 0.080 |
Why?
|
Time Factors | 7 | 2019 | 39957 | 0.080 |
Why?
|
Prospective Studies | 5 | 2024 | 54437 | 0.070 |
Why?
|
Female | 22 | 2024 | 392552 | 0.070 |
Why?
|
Water | 1 | 2014 | 1410 | 0.070 |
Why?
|
Prisons | 1 | 1989 | 174 | 0.070 |
Why?
|
Environmental Monitoring | 2 | 2004 | 1460 | 0.070 |
Why?
|
DNA, Bacterial | 2 | 2002 | 1470 | 0.070 |
Why?
|
Streptomycin | 2 | 2002 | 69 | 0.070 |
Why?
|
Child, Preschool | 4 | 2019 | 42225 | 0.070 |
Why?
|
Risk Factors | 9 | 2024 | 74241 | 0.070 |
Why?
|
Health Maintenance Organizations | 2 | 1999 | 658 | 0.070 |
Why?
|
Antibiotics, Antitubercular | 2 | 2002 | 99 | 0.070 |
Why?
|
Housing | 2 | 2013 | 669 | 0.070 |
Why?
|
Students, Nursing | 1 | 2006 | 45 | 0.070 |
Why?
|
Drug Resistance, Bacterial | 2 | 2011 | 1048 | 0.060 |
Why?
|
Antigens, Bacterial | 2 | 2013 | 1140 | 0.060 |
Why?
|
Risk Assessment | 4 | 2014 | 24022 | 0.060 |
Why?
|
Microscopy | 1 | 2011 | 904 | 0.060 |
Why?
|
Health Facilities | 1 | 2010 | 575 | 0.060 |
Why?
|
Bacterial Typing Techniques | 2 | 2002 | 262 | 0.060 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1991 | 2196 | 0.060 |
Why?
|
Bacteria | 1 | 2016 | 2190 | 0.060 |
Why?
|
Secondary Prevention | 3 | 2017 | 1472 | 0.060 |
Why?
|
Occupational Health Services | 3 | 2017 | 150 | 0.060 |
Why?
|
Middle Aged | 12 | 2024 | 220858 | 0.060 |
Why?
|
Public Health | 3 | 2019 | 2672 | 0.060 |
Why?
|
Minority Groups | 1 | 1991 | 1201 | 0.060 |
Why?
|
Ambulatory Care | 1 | 2015 | 2770 | 0.060 |
Why?
|
Young Adult | 4 | 2024 | 59222 | 0.060 |
Why?
|
Pericardiocentesis | 1 | 2004 | 78 | 0.060 |
Why?
|
Aviation | 1 | 2004 | 49 | 0.060 |
Why?
|
Exhalation | 1 | 2004 | 182 | 0.060 |
Why?
|
Teleradiology | 1 | 2004 | 52 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 2 | 1999 | 1191 | 0.050 |
Why?
|
Physicians | 1 | 2021 | 4584 | 0.050 |
Why?
|
Carbon Dioxide | 3 | 2022 | 1147 | 0.050 |
Why?
|
False Negative Reactions | 1 | 2004 | 573 | 0.050 |
Why?
|
Cardiac Tamponade | 1 | 2004 | 175 | 0.050 |
Why?
|
Mediastinum | 1 | 2004 | 267 | 0.050 |
Why?
|
Europe | 2 | 2019 | 3423 | 0.050 |
Why?
|
Child | 5 | 2019 | 80154 | 0.050 |
Why?
|
Sodium Chloride | 1 | 2004 | 584 | 0.050 |
Why?
|
Equipment Design | 2 | 2014 | 3510 | 0.050 |
Why?
|
Drug Costs | 1 | 2010 | 1183 | 0.050 |
Why?
|
Lung Compliance | 1 | 1982 | 200 | 0.050 |
Why?
|
Laboratories | 2 | 2002 | 462 | 0.050 |
Why?
|
Filtration | 2 | 2003 | 228 | 0.050 |
Why?
|
Alkalosis | 1 | 1981 | 55 | 0.050 |
Why?
|
Nursing Homes | 1 | 1989 | 1083 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2002 | 6067 | 0.050 |
Why?
|
Drug Delivery Systems | 1 | 2013 | 2223 | 0.050 |
Why?
|
Health Facility Environment | 1 | 2001 | 32 | 0.050 |
Why?
|
Lung Volume Measurements | 1 | 1982 | 375 | 0.050 |
Why?
|
Hospitals | 3 | 2002 | 3881 | 0.050 |
Why?
|
Program Development | 1 | 2007 | 1294 | 0.050 |
Why?
|
Remote Consultation | 1 | 2004 | 237 | 0.050 |
Why?
|
Pleural Effusion | 1 | 2004 | 341 | 0.050 |
Why?
|
Eye | 1 | 2005 | 713 | 0.050 |
Why?
|
Adolescent | 4 | 2014 | 88300 | 0.050 |
Why?
|
Computer Simulation | 2 | 2013 | 6224 | 0.050 |
Why?
|
Health Policy | 1 | 1993 | 2679 | 0.050 |
Why?
|
Photography | 1 | 2004 | 532 | 0.040 |
Why?
|
Recurrence | 2 | 2010 | 8457 | 0.040 |
Why?
|
Public Health Practice | 1 | 2002 | 219 | 0.040 |
Why?
|
Animal Testing Alternatives | 1 | 1999 | 15 | 0.040 |
Why?
|
Epitopes | 1 | 2006 | 2504 | 0.040 |
Why?
|
Patient Compliance | 3 | 1999 | 2688 | 0.040 |
Why?
|
Radiology Information Systems | 1 | 2004 | 529 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2014 | 4014 | 0.040 |
Why?
|
Students, Medical | 2 | 2017 | 1940 | 0.040 |
Why?
|
Radiographic Image Enhancement | 1 | 2004 | 877 | 0.040 |
Why?
|
United States | 7 | 2008 | 72341 | 0.040 |
Why?
|
Infant | 3 | 2018 | 36170 | 0.040 |
Why?
|
Tuberculosis, Bovine | 1 | 1998 | 8 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2002 | 2706 | 0.040 |
Why?
|
Methicillin Resistance | 1 | 1999 | 198 | 0.040 |
Why?
|
United States Occupational Safety and Health Administration | 1 | 1998 | 54 | 0.040 |
Why?
|
Nitroimidazoles | 1 | 2019 | 117 | 0.040 |
Why?
|
Diagnostic Errors | 2 | 2002 | 1265 | 0.040 |
Why?
|
Oxazoles | 1 | 2019 | 199 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2164 | 0.040 |
Why?
|
Vietnam | 1 | 2019 | 406 | 0.040 |
Why?
|
Hospitals, State | 1 | 1997 | 28 | 0.040 |
Why?
|
Reference Values | 1 | 2005 | 4921 | 0.040 |
Why?
|
Incidence | 5 | 2022 | 21366 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 4851 | 0.040 |
Why?
|
Pharmacies | 1 | 1999 | 168 | 0.040 |
Why?
|
Healthcare Disparities | 2 | 2010 | 3354 | 0.040 |
Why?
|
Triage | 1 | 2024 | 985 | 0.040 |
Why?
|
Russia | 2 | 2008 | 383 | 0.040 |
Why?
|
Laboratory Personnel | 1 | 2017 | 19 | 0.040 |
Why?
|
Radiography, Thoracic | 1 | 2004 | 1302 | 0.040 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2017 | 33 | 0.040 |
Why?
|
Victoria | 1 | 1996 | 64 | 0.030 |
Why?
|
Light | 1 | 2023 | 1348 | 0.030 |
Why?
|
Safety | 2 | 1993 | 1151 | 0.030 |
Why?
|
World Health Organization | 2 | 2019 | 1321 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2018 | 26200 | 0.030 |
Why?
|
Primary Prevention | 1 | 2003 | 1185 | 0.030 |
Why?
|
Acute Disease | 1 | 2006 | 7226 | 0.030 |
Why?
|
Case Management | 1 | 1997 | 272 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1791 | 0.030 |
Why?
|
Public Health Administration | 1 | 2017 | 242 | 0.030 |
Why?
|
Vitamin D | 1 | 2008 | 3301 | 0.030 |
Why?
|
Lung | 2 | 2004 | 9979 | 0.030 |
Why?
|
Pulmonary Surfactants | 1 | 2015 | 162 | 0.030 |
Why?
|
Biomedical Research | 1 | 2010 | 3434 | 0.030 |
Why?
|
Steam | 1 | 2014 | 32 | 0.030 |
Why?
|
Disease Progression | 2 | 2013 | 13511 | 0.030 |
Why?
|
New York City | 1 | 1996 | 730 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2010 | 15308 | 0.030 |
Why?
|
Human Rights | 1 | 2017 | 308 | 0.030 |
Why?
|
Microbial Viability | 1 | 2015 | 236 | 0.030 |
Why?
|
Boston | 2 | 2002 | 9327 | 0.030 |
Why?
|
HIV-1 | 1 | 1991 | 6851 | 0.030 |
Why?
|
Hypersensitivity, Delayed | 1 | 1995 | 490 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2008 | 12341 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2015 | 696 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 10218 | 0.030 |
Why?
|
Africa, Southern | 1 | 2013 | 60 | 0.030 |
Why?
|
Lipid Peroxidation | 1 | 2014 | 271 | 0.030 |
Why?
|
Cattle | 1 | 1998 | 3818 | 0.030 |
Why?
|
Social Conditions | 1 | 2013 | 120 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2014 | 80675 | 0.030 |
Why?
|
Cell Wall | 1 | 2015 | 417 | 0.020 |
Why?
|
Puerto Rico | 1 | 1993 | 378 | 0.020 |
Why?
|
Morbidity | 1 | 1997 | 1751 | 0.020 |
Why?
|
Cost of Illness | 1 | 2002 | 1936 | 0.020 |
Why?
|
Echocardiography | 1 | 2004 | 5006 | 0.020 |
Why?
|
HIV | 1 | 2018 | 1581 | 0.020 |
Why?
|
Mass Screening | 2 | 2018 | 5426 | 0.020 |
Why?
|
Skin | 1 | 2005 | 4473 | 0.020 |
Why?
|
Equipment Contamination | 2 | 2002 | 182 | 0.020 |
Why?
|
Genotype | 2 | 2002 | 12985 | 0.020 |
Why?
|
Aged | 3 | 2024 | 169292 | 0.020 |
Why?
|
Drug Synergism | 1 | 2015 | 1756 | 0.020 |
Why?
|
Molecular Structure | 1 | 2015 | 1875 | 0.020 |
Why?
|
Species Specificity | 1 | 1995 | 2406 | 0.020 |
Why?
|
Research Design | 1 | 2006 | 6180 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 1995 | 1381 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2015 | 3057 | 0.020 |
Why?
|
Tuberculin | 1 | 2009 | 64 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3134 | 0.020 |
Why?
|
Health Care Costs | 1 | 2002 | 3239 | 0.020 |
Why?
|
Bicarbonates | 2 | 1981 | 292 | 0.020 |
Why?
|
Population Surveillance | 1 | 1999 | 2598 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2004 | 12976 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 1995 | 1385 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2019 | 1463 | 0.020 |
Why?
|
Algorithms | 1 | 2008 | 14025 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2014 | 2227 | 0.020 |
Why?
|
Models, Biological | 1 | 2004 | 9458 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2013 | 858 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1989 | 880 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3923 | 0.020 |
Why?
|
Skin Tests | 1 | 2009 | 638 | 0.020 |
Why?
|
Organizational Case Studies | 1 | 2007 | 301 | 0.020 |
Why?
|
Radiation Tolerance | 1 | 1989 | 478 | 0.020 |
Why?
|
Opportunistic Infections | 1 | 1989 | 376 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 1991 | 934 | 0.020 |
Why?
|
Surface Tension | 1 | 2004 | 43 | 0.020 |
Why?
|
Isotonic Solutions | 1 | 2004 | 117 | 0.010 |
Why?
|
Retreatment | 1 | 2006 | 598 | 0.010 |
Why?
|
Viscosity | 1 | 2004 | 335 | 0.010 |
Why?
|
Phenotype | 1 | 2002 | 16575 | 0.010 |
Why?
|
Length of Stay | 1 | 1997 | 6417 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 1997 | 7804 | 0.010 |
Why?
|
Data Compression | 1 | 2004 | 68 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2000 | 7400 | 0.010 |
Why?
|
Personnel, Hospital | 1 | 1985 | 285 | 0.010 |
Why?
|
Colony Count, Microbial | 1 | 2003 | 328 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1995 | 2223 | 0.010 |
Why?
|
Electronic Mail | 1 | 2004 | 213 | 0.010 |
Why?
|
Stomach Ulcer | 1 | 1981 | 122 | 0.010 |
Why?
|
Respiratory Tract Infections | 1 | 1989 | 1009 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1982 | 2087 | 0.010 |
Why?
|
Quality Control | 1 | 2004 | 833 | 0.010 |
Why?
|
Acid-Base Equilibrium | 1 | 1981 | 181 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2004 | 20588 | 0.010 |
Why?
|
Elastin | 1 | 1982 | 298 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2003 | 1624 | 0.010 |
Why?
|
Sentinel Surveillance | 1 | 2002 | 291 | 0.010 |
Why?
|
Particle Size | 1 | 2004 | 1649 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2002 | 958 | 0.010 |
Why?
|
Pharmaceutical Preparations | 1 | 2007 | 1086 | 0.010 |
Why?
|
Pressure | 1 | 1982 | 1155 | 0.010 |
Why?
|
Urban Population | 1 | 2006 | 2036 | 0.010 |
Why?
|
Vomiting | 1 | 1981 | 650 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2009 | 5478 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10516 | 0.010 |
Why?
|
Specimen Handling | 1 | 2002 | 702 | 0.010 |
Why?
|
Rural Population | 1 | 2008 | 2277 | 0.010 |
Why?
|
Probability | 1 | 2003 | 2478 | 0.010 |
Why?
|
Patient-Centered Care | 1 | 2007 | 1427 | 0.010 |
Why?
|
Cost-Benefit Analysis | 2 | 2001 | 5493 | 0.010 |
Why?
|
Health Planning | 1 | 1998 | 231 | 0.010 |
Why?
|
Organ Size | 1 | 1982 | 2253 | 0.010 |
Why?
|
Acidosis | 1 | 1979 | 269 | 0.010 |
Why?
|
Mice | 1 | 2004 | 81330 | 0.010 |
Why?
|
Communicable Diseases | 1 | 2004 | 873 | 0.010 |
Why?
|
ROC Curve | 1 | 2004 | 3584 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2013 | 10203 | 0.010 |
Why?
|
Alcoholism | 1 | 1986 | 1973 | 0.010 |
Why?
|
Morals | 1 | 1998 | 289 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 30004 | 0.010 |
Why?
|
Collagen | 1 | 1982 | 2635 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 1991 | 5333 | 0.010 |
Why?
|
Clinical Protocols | 1 | 1999 | 1436 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2006 | 12052 | 0.010 |
Why?
|
Disease Management | 1 | 1999 | 2507 | 0.000 |
Why?
|
Rats | 1 | 1982 | 23705 | 0.000 |
Why?
|
Maximum Allowable Concentration | 1 | 1985 | 63 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2004 | 20118 | 0.000 |
Why?
|
Radioactive Pollutants | 1 | 1985 | 13 | 0.000 |
Why?
|
Cohort Studies | 1 | 2008 | 41496 | 0.000 |
Why?
|
Ethylene Oxide | 1 | 1985 | 28 | 0.000 |
Why?
|
Mercury Poisoning | 1 | 1985 | 32 | 0.000 |
Why?
|
Parasitic Diseases | 1 | 1985 | 76 | 0.000 |
Why?
|
Formaldehyde | 1 | 1985 | 357 | 0.000 |
Why?
|
Accidents, Occupational | 1 | 1985 | 249 | 0.000 |
Why?
|
Radiation Protection | 1 | 1985 | 426 | 0.000 |
Why?
|
Work Schedule Tolerance | 1 | 1985 | 553 | 0.000 |
Why?
|
Hydrochloric Acid | 1 | 1979 | 76 | 0.000 |
Why?
|
Virus Diseases | 1 | 1985 | 716 | 0.000 |
Why?
|
Bacterial Infections | 1 | 1985 | 1390 | 0.000 |
Why?
|
Dogs | 1 | 1979 | 3832 | 0.000 |
Why?
|
Blood-Brain Barrier | 1 | 1979 | 1028 | 0.000 |
Why?
|
Respiration | 1 | 1979 | 1657 | 0.000 |
Why?
|
Stress, Psychological | 1 | 1985 | 4487 | 0.000 |
Why?
|